{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:14:57Z","timestamp":1792703697220,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.esmorw.2025.100114","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T16:02:51Z","timestamp":1740499371000},"page":"100114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Impact of travel costs on disparities in precision oncology clinical trials"],"prefix":"10.1016","volume":"7","author":[{"given":"Y.","family":"Uehara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Katsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Shimoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10351","key":"10.1016\/j.esmorw.2025.100114_bib1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0140-6736(22)01390-3","article-title":"Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials","volume":"400","author":"Chihara","year":"2022","journal-title":"Lancet"},{"issue":"30","key":"10.1016\/j.esmorw.2025.100114_bib2","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1200\/JCO.21.02125","article-title":"Ethical considerations for phase I trials in oncology","volume":"40","author":"Bittlinger","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmorw.2025.100114_bib3","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1200\/OP.22.00122","article-title":"The road less traveled: transportation barriers to cancer care delivery in the rural patient population","volume":"18","author":"Wercholuk","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"10.1016\/j.esmorw.2025.100114_bib4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jamaoncol.2023.6767","article-title":"Federal transportation regulations limit access to clinical trials and oncology care","volume":"10","author":"Pancoe","year":"2024","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.esmorw.2025.100114_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.33188","article-title":"Travel time and distance and participation in precision oncology trials at the National Cancer Center Hospital","volume":"6","author":"Uehara","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"22","key":"10.1016\/j.esmorw.2025.100114_bib6","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.19.00175","article-title":"Impact of travel time on health care costs and resource use by phase of care for older patients with cancer","volume":"37","author":"Rocque","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100114_bib7","doi-asserted-by":"crossref","first-page":"e915","DOI":"10.1200\/OP.21.00328","article-title":"Implementation of a multisite financial reimbursement program in cancer clinical trials integrated with patient navigation: a pilot randomized clinical trial","volume":"18","author":"Borno","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"8","key":"10.1016\/j.esmorw.2025.100114_bib8","first-page":"655","article-title":"Barriers to clinical trial participation as perceived by oncologists and patients","volume":"5","author":"Meropol","year":"2007","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100114_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jamaoncol.2015.3924","article-title":"Patient income level and cancer clinical trial participation: a prospective survey study","volume":"2","author":"Unger","year":"2016","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.esmorw.2025.100114_bib10","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1634\/theoncologist.2017-0628","article-title":"At what cost to clinical trial enrollment? A retrospective study of patient travel burden in cancer clinical trials","volume":"23","author":"Borno","year":"2018","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100114_bib11","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1634\/theoncologist.2015-0068","article-title":"Recognizing the financial burden of cancer patients in clinical trials","volume":"20","author":"Nipp","year":"2015","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100114_bib12","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamaoncol.2023.0248","article-title":"Enrollment barriers for molecular targeted trials","volume":"9","author":"Paydary","year":"2023","journal-title":"JAMA Oncol"},{"issue":"18","key":"10.1016\/j.esmorw.2025.100114_bib13","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.23.01030","article-title":"National estimates of the participation of patients with cancer in clinical research studies based on commission on cancer accreditation data","volume":"42","author":"Unger","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.esmorw.2025.100114_bib14","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.2014.60.4165","article-title":"Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials","volume":"33","author":"Meric-Bernstam","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100114_bib15","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.esmorw.2025.100114_bib16","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1111\/cas.15586","article-title":"Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice","volume":"113","author":"Ida","year":"2022","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100114_bib17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13073-016-0364-2","article-title":"Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the princess Margaret IMPACT\/COMPACT trial","volume":"8","author":"Stockley","year":"2016","journal-title":"Genome Med"},{"key":"10.1016\/j.esmorw.2025.100114_bib18","article-title":"Clinical use of precision oncology decision support","volume":"2017","author":"Johnson","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2025.100114_bib19","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/cas.13969","article-title":"Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study","volume":"110","author":"Sunami","year":"2019","journal-title":"Cancer Sci"},{"issue":"11","key":"10.1016\/j.esmorw.2025.100114_bib20","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"9","key":"10.1016\/j.esmorw.2025.100114_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237802","article-title":"Clinical and analytical validation of FoundationOne liquid CDx, a novel 324-gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin","volume":"15","author":"Woodhouse","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.esmorw.2025.100114_bib22","article-title":"Prospective feasibility study for using cell-free circulating tumor DNA-guided therapy in refractory metastatic solid cancers: an interim analysis","volume":"1","author":"Kim","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"10.1016\/j.esmorw.2025.100114_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.45081","article-title":"Concordance between recommendations from multidisciplinary molecular tumor boards and central consensus for cancer treatment in Japan","volume":"5","author":"Naito","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.esmorw.2025.100114_bib24","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","article-title":"C-CAT: the national datacenter for cancer genomic medicine in Japan","volume":"12","author":"Kohno","year":"2022","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.esmorw.2025.100114_bib25","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/cas.15651","article-title":"Selection bias due to delayed comprehensive genomic profiling in Japan","volume":"114","author":"Tamura","year":"2023","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100114_bib26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/jamaoncol.2023.5120","article-title":"A\u00a0learning program for treatment recommendations by molecular tumor boards and artificial intelligence","volume":"10","author":"Sunami","year":"2024","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.esmorw.2025.100114_bib27","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamaoncol.2022.1664","article-title":"A\u00a0new approach to simplifying and harmonizing cancer clinical trials-standardizing eligibility criteria","volume":"8","author":"Gerber","year":"2022","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.esmorw.2025.100114_bib28","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1634\/theoncologist.2018-0808","article-title":"Referrals to a phase I clinic and trial enrollment in the molecular screening era","volume":"24","author":"Tan","year":"2019","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.esmorw.2025.100114_bib29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"10.1016\/j.esmorw.2025.100114_bib31","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2008.19.5081","article-title":"Prospective validation of a prognostic score to improve patient selection for oncology phase I trials","volume":"27","author":"Arkenau","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmorw.2025.100114_bib32","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1158\/1078-0432.CCR-11-2217","article-title":"Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience","volume":"18","author":"Wheler","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.esmorw.2025.100114_bib33","first-page":"1","article-title":"mice: Multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J\u00a0Stat Softw"},{"issue":"3","key":"10.1016\/j.esmorw.2025.100114_bib34","first-page":"69","article-title":"Statistics corner: a guide to appropriate use of correlation coefficient in medical research","volume":"24","author":"Mukaka","year":"2012","journal-title":"Malawi Med J"},{"key":"10.1016\/j.esmorw.2025.100114_bib37","first-page":"105","volume":"39","author":"Nipp","year":"2019"},{"issue":"8","key":"10.1016\/j.esmorw.2025.100114_bib38","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/cncr.35145","article-title":"A\u00a0call to action to advance patient-focused and decentralized clinical trials","volume":"130","author":"Harvey","year":"2024","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.esmorw.2025.100114_bib39","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamaoncol.2023.6565","article-title":"Decentralized clinical trials as a new paradigm of trial delivery to improve equity of access","volume":"10","author":"Underhill","year":"2024","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.esmorw.2025.100114_bib41","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100114_bib42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13073-021-00969-w","article-title":"Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-na\u00efve study","volume":"13","author":"Sicklick","year":"2021","journal-title":"Genome Med"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100114_bib43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.annonc.2022.07.010","article-title":"Cancer: slaying the nine-headed Hydra","volume":"34","author":"Adashek","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100114_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100647","article-title":"Targeting the FGF\/FGFR axis and its co-alteration allies","volume":"7","author":"Uehara","year":"2022","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100114_bib45","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1158\/2159-8290.CD-22-1377","article-title":"N-of-1 trials in cancer drug development","volume":"13","author":"Gouda","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100114_bib46","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-020-18613-3","article-title":"Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy","volume":"11","author":"Kato","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.esmorw.2025.100114_bib47","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2023.7314","article-title":"Analysis and optimization of equitable US cancer clinical trial center access by travel time","volume":"10","author":"Lee","year":"2024","journal-title":"JAMA Oncol"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820125000037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820125000037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T22:48:14Z","timestamp":1747349294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820125000037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":43,"alternative-id":["S2949820125000037"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100114","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of travel costs on disparities in precision oncology clinical trials","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100114"}}